Ingersoll Rand has completed its acquisition of Scinomix, Inc., a U.S.-based leader in laboratory automation for clinical, pharmaceutical and biotechnology markets. The deal enhances IR’s existing life sciences portfolio by integrating Scinomix’s proprietary labeling, handling and capping automation technologies with IR’s fluid and gas management solutions. According to company statements, this bolt-on acquisition enables IR to offer end-to-end workflow systems—from sample preparation through analysis—addressing a combined addressable market projected to exceed $5 billion by 2028. IR expects cross-selling opportunities to drive 15% annual revenue growth in its Life Sciences segment over the next three years.

The transaction was executed at a pre-synergy purchase multiple of approximately 10 times Scinomix’s forecasted 2025 Adjusted EBITDA. Management projects $12 million in annual cost and revenue synergies by 2027, primarily through optimized manufacturing footprint and unified R&D programs. IR plans to finance the acquisition with a mix of cash on hand and incremental term debt, maintaining its net leverage ratio comfortably below 2.5x covenant levels. Analysts estimate the deal could be accretive to IR’s free cash flow per share in fiscal 2026, supporting the company’s commitment to a 10%–12% annual dividend growth rate.

IR has established a dedicated integration team to align Scinomix’s operations with IR’s global supply chain and customer support infrastructure. The companies will consolidate select administrative functions while preserving Scinomix’s specialized engineering workforce in Charlottesville, Virginia. This integration is expected to shorten R&D timelines for next-generation automation modules by six months. IR’s CEO highlighted that the combined organization will accelerate product roadmap execution, positioning the company to capture increased demand from vaccine manufacturers and high-throughput testing laboratories worldwide.